Article
Gastroenterology & Hepatology
Shinji Okabayashi, Hajime Yamazaki, Keiichi Tominaga, Miki Miura, Shintaro Sagami, Katsuyoshi Matsuoka, Yoshiharu Yamaguchi, Toshihiro Noake, Keiji Ozeki, Ryosuke Miyazaki, Toshiaki Kamano, Tomohiro Fukuda, Kyoko Yoshioka, Katsuyoshi Ando, Masakatsu Fukuzawa, Akira Andoh, Yosuke Yamamoto, Toshifumi Hibi, Taku Kobayashi
Summary: This study aimed to evaluate the effectiveness and risks of treatment in older-onset ulcerative colitis (UC) patients. The results showed that older-onset patients had lower effectiveness with intravenous steroids and higher risks of surgery and adverse events.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Pharmacology & Pharmacy
Alix Demaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Summary: This review aims to analyze the population PK models of infliximab (IFX) in patients with ulcerative colitis (UC) and acute severe UC (ASUC), and assess the impact of disease activity on IFX PK. The results showed that there are still many gaps in the current research, such as a limited number of models specifically developed for UC patients, a lack of studies on severe UC patients, and a lack of evaluation of predictive performance for the models. Therefore, more comprehensive research and adequate reporting and evaluation of the models are needed for clinical application.
Review
Gastroenterology & Hepatology
Nicholas E. Burr, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: In a network meta-analysis, upadacitinib 45 mg once daily ranked first for clinical remission in all patients, patients naive to anti-TNF-alpha drugs and patients previously exposed. Infliximab 10 mg/kg ranked first for endoscopic improvement. Most drugs were safe and well tolerated.
Article
Gastroenterology & Hepatology
Stefano Festa, Maria L. Scribano, Daniela Pugliese, Cristina Bezzio, Mariabeatrice Principi, Davide G. Ribaldone, Mariangela Allocca, Giammarco Mocci, Giorgia Bodini, Rocco Spagnuolo, Piero Vernia, Silvia Mazzuoli, Francesco Costa, Brigida Barberio, Rocco Cosintino, Giulia Zerboni, Annalisa Aratari, Alessandro Armuzzi, Claudio Papi
Summary: Long-term follow-up of patients with acute severe ulcerative colitis who avoided early colectomy showed that the majority of patients did not require immediate surgery. Patients who responded to steroids or rescue therapy had a lower risk of long-term colectomy, while those previously exposed to antitumour necrosis factor-alpha agents or with refractory cases during acute attacks had a higher risk of long-term colectomy.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Article
Gastroenterology & Hepatology
Kit Curtius, Misha Kabir, Ibrahim Al Bakir, Chang Ho Ryan Choi, Juanda L. Hartono, Michael Johnson, James E. East, James O. Lindsay, Roser Vega, Siwan Thomas-Gibson, Janindra Warusavitarne, Ana Wilson, Trevor A. Graham, Ailsa Hart
Summary: This study identified that patients with large, unresected, multifocal LGD and recent moderate/severe inflammation are at highest risk of developing advanced neoplasia. Personalised risk prediction provided via the Ulcerative Colitis-Cancer Risk Estimator can support treatment decision-making.
Review
Pharmacology & Pharmacy
Jing Zhou, Jialing Liu, Yangyang Gao, Liwei Shen, Sheng Li, Simin Chen
Summary: Ulcerative colitis is a chronic inflammatory bowel disease with unclear etiology, involving complex factors such as immunity, heredity, environment, and intestinal microbiota dysregulation. MicroRNA plays a crucial role in the pathogenesis of UC, particularly in immune regulation, gut microbiota dysregulation, and colitis-associated cancer. It has the potential to serve as a novel diagnostic marker and therapeutic target for UC.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Alex Adams, Vipin Gupta, Waled Mohsen, Thomas P. Chapman, Deloshaan Subhaharan, Pradeep Kakkadasam Ramaswamy, Sudheer Kumar, Saurabh Kedia, Colleen G. C. McGregor, Tim Ambrose, Bruce D. George, Rebecca Palmer, Oliver Brain, Alissa Walsh, Vineet Ahuja, Simon P. L. Travis, Jack Satsangi
Summary: The changes in acute severe colitis (ASC) management have resulted in improved outcomes. A simple predictive model can be used to identify patients who will not respond to steroids upon admission.
Article
Pediatrics
Ruth Garcia-Romero, Jose Miguel Martinez de Zabarte Fernandez, Gemma Pujol-Muncunill, Ester Donat-Aliaga, Oscar Segarra-Canton, Inaki Irastorza-Terradillos, Enrique Medina-Benitez, Carlos Jose Ruiz-Hernandez, Marta Carrillo-Palau, Ignacio Ros-Arnal, Alejandro Rodriguez-Martinez, Laura Escartin-Madurga, Carolina Gutierrez-Junquera, Saioa Vicente-Santamaria, Marta Velasco Rodriguez-Belvis, Sonia Fernandez-Fernandez, Jose Ramon Alberto-Alonso, Montserrat Montraveta, Ricardo Torres-Peral, Maria Navalon-Rubio, Victor Manuel Navas-Lopez, Javier Martin de Carpi
Summary: This study assessed the effectiveness and safety of Vedolizumab in children with inflammatory bowel disease, showing that it is a safe and effective option for achieving clinical remission in pediatric patients with primary failure or loss of response to other treatments, especially in UC. High clinical remission rates were observed in pediatric patients refractory to anti-TNF compared to those reported in adults, with few publications on pediatric populations treated with Vedolizumab and with long-term follow-up (52 weeks).
EUROPEAN JOURNAL OF PEDIATRICS
(2021)
Article
Gastroenterology & Hepatology
Robert Gilmore, Wei Lian Tan, Richard Fernandes, Yoon-Kyo An, Jakob Begun
Summary: This study found that upadacitinib may be a safe and effective salvage therapy for patients with steroid-refractory acute severe ulcerative colitis who have previously failed to respond to infliximab therapy. Prospective studies are needed to determine the safety and efficacy of upadacitinib use in this setting before routine use can be recommended.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Casper Steenholdt, Pernille Dige Ovesen, Jorn Brynskov, Jakob Benedict Seidelin
Summary: This systematic review analyzed the efficacy, safety, and integration of Tofacitinib in the treatment of acute severe ulcerative colitis (ASUC). The results showed that Tofacitinib has promising results in ASUC with high short-term colectomy-free survival. However, larger and high-quality studies are still needed to further evaluate its effectiveness.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Medicine, General & Internal
Benjamin L. Gordon, Robert Battat
Summary: Therapeutic drug monitoring (TDM) is a useful strategy in ulcerative colitis (UC), particularly in acute severe UC (ASUC). While there is limited data available for the use of TDM of infliximab in ASUC, observational data suggest that higher serum infliximab concentrations and lower clearance are associated with better clinical outcomes and decreased rates of colectomy. However, more studies are needed to evaluate optimal dosing and TDM targets in this population.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Alka A. Potdar, Shishir Dube, Takeo Naito, Katherine Li, Gregory Botwin, Talin Haritunians, Dalin Li, David Casero, Shaohong Yang, Janine Bilsborough, Jacqueline G. Perrigoue, Lee A. Denson, Mark Daly, Stephan R. Targan, Phillip Fleshner, Jonathan Braun, Subra Kugathasan, Thaddeus S. Stappenbeck, Dermot P. B. McGovern
Summary: The study identified differences in intestinal ACE2 expression levels in patients with Crohn's disease and ulcerative colitis, associated with inflammation and disease severity. Treatment with anti-cytokine therapy restored ACE2 expression, potentially impacting outcomes of severe acute respiratory syndrome coronavirus 2 infection.
Article
Gastroenterology & Hepatology
Nathaniel A. Cohen, Maryam Zafer, Namrata Setia, Michael J. Anderson, Atsushi Sakuraba, Sushila Dalal, Joel Pekow, Russell D. Cohen, David T. Rubin, Dejan Micic
Summary: This study found that serum CMV PCR can be used as a non-invasive test for diagnosing CMV colitis in UC patients, and it has excellent negative predictive value and a strong correlation with CMV positivity on histology.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Mathieu Uzzan, Clement Bresteau, David Laharie, Carmen Stefanescu, Christophe Bellanger, Franck Carbonnel, Melanie Serrero, Stephanie Viennot, Maria Nachury, Aurelien Amiot, Romain Altwegg, Laurence Picon, Stephane Nahon, Lucine Vuitton, Philippe Ah Soune, Julien Kirchgesner, Laurent Peyrin-Biroulet, Yoram Bouhnik
Summary: The study evaluated the effectiveness and safety of tofacitinib as rescue therapy in UC patients hospitalized for flare. Results showed high rates of colectomy-free survival, clinical response, and clinical remission with tofacitinib treatment. Safety profile of tofacitinib was favorable with no deaths observed and only a few adverse events reported. Further validation in controlled trials is needed to confirm the promising potential of tofacitinib in hospitalized UC patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Saurabh Kedia, Tarini Shankar Ghosh, Saransh Jain, Anbumani Desigamani, Ashok Kumar, Vipin Gupta, Sawan Bopanna, Dawesh P. Yadav, Sandeep Goyal, Govind Makharia, Simon P. L. Travis, Bhabatosh Das, Vineet Ahuja
Summary: The gut microbiome of patients with acute severe colitis (ASC) is characterized by lower diversity compared to mild-moderate UC or healthy controls (HCs). The microbiome composition in ASC is increasingly unstable, with distinct abundance of specific genera compared to UC and HCs. Mild-moderate UC falls within the spectrum of gut microbial diversity.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Letter
Gastroenterology & Hepatology
Charlie W. Lees, Tariq Ahmad, Christopher Andrew Lamb, Nick Powell, Shahida Din, Rachel Cooney, Nicholas A. Kennedy, Rachel Ainley, Ruth Wakeman, Christian Philipp Selinger
Article
Gastroenterology & Hepatology
Nicholas A. Kennedy, Malik Janjua, Neil Chanchlani, Simeng Lin, Claire Bewshea, Rachel Nice, Timothy J. McDonald, Cressida Auckland, Lorna W. Harries, Merlin Davies, Stephen Michell, Klaartje B. Kok, Christopher A. Lamb, Philip J. Smith, Ailsa L. Hart, Richard C. G. Pollok, Charlie W. Lees, Rosemary J. Boyton, Daniel M. Altmann, Shaji Sebastian, Nicholas Powell, James R. Goodhand, Tariq Ahmad
Summary: This study found that a third dose of an mRNA-based vaccine can boost antibody responses and immunity in infliximab-treated patients with IBD. However, these patients had lower antibody concentrations compared to those treated with vedolizumab and were more likely to experience breakthrough infections and reinfections.
Review
Gastroenterology & Hepatology
Shaji Sebastian, Jonathan P. Segal, Charlotte Hedin, Gianluca Pellino, Paulo Gustavo Kotze, Michel Adamina, Marjo Campmans-Kuijpers, Justin Davies, Annemarie C. de Vries, Ana Gutierrez Casbas, Alaa El-Hussuna, Pascal Juillerat, Susanna Meade, Monica Millan, Antonino Spinelli
Summary: This article provides expert consensus practice recommendations for peri-operative care in patients with inflammatory bowel diseases (IBD) to optimize surgical outcomes.
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Gastroenterology & Hepatology
Andrew Chilton, Olga Dziedziak, Sean Jones, Ajay M. Verma
FRONTLINE GASTROENTEROLOGY
(2023)
Editorial Material
Gastroenterology & Hepatology
Aamir Saifuddin, Alexandra J. Kent, Shameer J. J. Mehta, Shaji Sebastian
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Pediatrics
Greg Young, Janet E. Berrington, Stephen Cummings, Jon Dorling, Andrew K. Ewer, Alessandra Frau, Lauren Lett, Chris Probert, Ed Juszczak, John Kirby, Lauren C. Beck, Victoria L. Renwick, Christopher Lamb, Clare Lanyon, William McGuire, Christopher Stewart, Nicholas Embleton
Summary: This study investigated the impact of supplemental bovine lactoferrin on the gut microbiome and metabolome of preterm infants. The results showed minimal impacts of lactoferrin on the microbiome composition, while hospital site and postnatal age had a larger impact. This study provides guidance for future trial design.
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION
(2023)
Article
Gastroenterology & Hepatology
Matthew J. Lee, ENiGMA CODE collaborators
Summary: The aim of this study was to develop a core descriptor set for reporting Crohn's anal fistula (CAF) research. Through an international modified Delphi process, a consensus was reached on 37 core descriptors within six domains, which may aid in transparent reporting for future studies.
COLORECTAL DISEASE
(2023)
Review
Immunology
Kristian C. Williams, Abigail Gault, Amy E. Anderson, Christopher J. Stewart, Christopher A. Lamb, R. Ally Speight, Neil Rajan, Ruth Plummer, Arthur G. Pratt
Summary: Checkpoint inhibitors (CPIs) disrupt immune checkpoint molecules to block regulatory immune signals, but can cause immune-related adverse events (irAEs) similar to autoimmune diseases. Understanding irAE pathobiology may lead to targeted mitigation strategies and predictive biomarkers. This review focuses on irAEs in the gut, skin, and synovial joints, comparing them to immune-mediated diseases. Studies show dysregulation of cytokines, T-cell infiltration, and potential therapeutic opportunities for irAEs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D'Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A. Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel, Erik Hertervig
Summary: This study aimed to compare the relapse rate and time in remission over 2 years between patients continuing combination therapy, stopping infliximab, or stopping immunosuppressant therapy for Crohn's disease. The results showed that stopping infliximab had a higher relapse rate compared to stopping immunosuppressant therapy, suggesting that stopping immunosuppressant therapy may be a preferable strategy for treatment de-escalation.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Urology & Nephrology
Surekha Annadanam, Gunjan Garg, Angela Fagerlin, Corey Powell, Emily Chen, Jonathan H. Segal, Akinlolu Ojo, Julie Wright Nunes
Summary: Multidisciplinary care for chronic kidney disease (CKD) has been associated with improved clinical outcomes. However, research on the impact of multidisciplinary care on patient-centered outcomes is limited. This study examined the association between multidisciplinary care and four patient-centered outcomes.
Editorial Material
Gastroenterology & Hepatology
Sonika Sethi, Aditi Kumar, Shiluka Dias, Jonathan Blackwell, Matthew J. Brookes, Jonathan P. Segal
Summary: This article is related to the papers by Sethi et al. To access these articles, visit the link.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Shaji Sebastian
INDIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Neil Chanchlani, Simeng Lin, Rebecca Smith, Christopher Roberts, Rachel Nice, Timothy J. McDonald, Benjamin Hamilton, Maria Bishara, Claire Bewshea, Nicholas A. Kennedy, James R. Goodhand, Tariq Ahmad, PANTS Consortium
Summary: Low vitamin D concentrations are common in patients with inflammatory bowel disease, but this study found that pretreatment vitamin D concentrations did not predict response to anti-TNF treatment in patients with Crohn's disease.
CROHNS & COLITIS 360
(2023)
Review
Gastroenterology & Hepatology
Luis Miguel Nieto, Afia Iqbal, Danilo Vinci, Danujan Sriranganathan, Gianluca Pellino, Jonathan P. Segal
Summary: Restorative proctocolectomy (RPC) is the most common surgical procedure for restoring gastrointestinal continuity after colon and rectal surgery. Pouchitis is a common complication, and various modalities can be used for diagnosis. This systematic review and meta-analysis aimed to explore the sensitivity and specificity of these diagnostic modalities. The results showed that fecal lactoferrin had the highest pooled sensitivity and specificity of 98% and 88% respectively, followed by imaging modalities, and fecal calprotectin had sensitivities and specificities of 87% and 79% and 74% and 81% respectively. Fecal biomarkers, particularly lactoferrin, and imaging modalities may play an important role in diagnosing pouchitis.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Vikram Rao, Ella Cockburn, Jonathan P. Segal
INFLAMMATORY BOWEL DISEASES
(2023)